Shares of Bristol-Myers Squibb Co (NYSE:BMY) ended Monday session in red amid volatile trading. The shares closed down -0.09 points or -0.18% at $50.91 with 11.33 million shares getting traded. Post opening the session at $51.05, the shares hit an intraday low of $50.65 and an intraday high of $51.62 and the price vacillated in this range throughout the day. The company has a market cap of $83.51 billion and the numbers of outstanding shares have been calculated to be 1.67 billion shares.
Bristol-Myers Squibb Co (BMY) announced new data presentations from studies evaluating Opdivo (nivolumab) as monotherapy or in combination with Yervoy (ipilimumab) in the treatment of melanoma, including new research on the efficacy and safety of the combination in melanoma patients with high unmet need including those with elevated serum lactate dehydrogenase (LDH) and brain metastases. Additional presentations will also highlight new data on health economics and real-world outcomes in patients living with the disease.
The data, to be presented at the Society for Melanoma Research (SMR) 2016 Congress in Boston, MA from November 6-9, underscore the Company’s continued leadership in advancing melanoma treatment research and deepening our scientific understanding of the potential of Immuno-Oncology as a treatment option including the potential survival impact of combination therapies.
Shares of Horizon Pharma PLC (NASDAQ:HZNP) ended Monday session in red amid volatile trading. The shares closed down -1.13 points or -6.33% at $16.72 with 3.37 million shares getting traded. Post opening the session at $17.75, the shares hit an intraday low of $16.66 and an intraday high of $17.80 and the price vacillated in this range throughout the day. The company has a market cap of $2.79 billion and the numbers of outstanding shares have been calculated to be 160.90 million shares.
Horizon Pharma PLC (HZNP) announced that it has completed the acquisition of Raptor Pharmaceutical Corp. (RPTP).
“The acquisition of Raptor directly aligns with our long-term strategy and evolution into a rare disease focused company, where now more than half of our medicines are used to treat patients with rare diseases,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. “The added infrastructure in Europe and other key international markets will further benefit the access to both our current and newly acquired medicines as well as position us for the potential introduction of ACTIMMUNE® for Friedreich’s ataxia in Europe in future years if the results of the Phase 3 trial are positive.”